Cargando…
Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer
With the rapidly evolving of immune checkpoint inhibitors (ICIs), it has shown remarkable clinical benefits in treating various cancers. However, immune-related adverse events (irAEs) remain a significant challenge in the management of patients undergoing immunotherapy. There are limited data about...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616240/ https://www.ncbi.nlm.nih.gov/pubmed/37915573 http://dx.doi.org/10.3389/fimmu.2023.1270828 |
_version_ | 1785129350251675648 |
---|---|
author | He, Shengxiu Wang, Liang Sun, Yan Du, Huakun Yu, Xiaomin |
author_facet | He, Shengxiu Wang, Liang Sun, Yan Du, Huakun Yu, Xiaomin |
author_sort | He, Shengxiu |
collection | PubMed |
description | With the rapidly evolving of immune checkpoint inhibitors (ICIs), it has shown remarkable clinical benefits in treating various cancers. However, immune-related adverse events (irAEs) remain a significant challenge in the management of patients undergoing immunotherapy. There are limited data about immunotherapy re-challenge in patients with renal clear cell cancer who had irAE in the initial ICI therapy. In this study, we reported the case of a patient with advanced renal clear cell cancer who developed serious irAEs but also achieved a partial remission of tumor after ICI combined with pazopanib in the first-line treatment. After intravenous methylprednisolone therapy for two weeks, the patient fully recovered from treatment-related toxicities. After a multidisciplinary treatment (MDT) discussion and a communication with the patient, the decision was made to undergo a new fully humanized programmed death 1 (PD-1) agent, zimberelimab, combined with pazopanib for immune restart therapy. After two cycles of treatment, the patient demonstrated a partial response (PR), and the disease remained in continuous remission without any irAE at our last follow-up after 14 months’ treatment. Re-challenging with immunotherapy after irAEs is an emerging strategy that offers the potential for additional clinical benefits to previously responding patients. However, careful patient selection and monitoring are essential to maximize the safety and efficacy of this approach. |
format | Online Article Text |
id | pubmed-10616240 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106162402023-11-01 Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer He, Shengxiu Wang, Liang Sun, Yan Du, Huakun Yu, Xiaomin Front Immunol Immunology With the rapidly evolving of immune checkpoint inhibitors (ICIs), it has shown remarkable clinical benefits in treating various cancers. However, immune-related adverse events (irAEs) remain a significant challenge in the management of patients undergoing immunotherapy. There are limited data about immunotherapy re-challenge in patients with renal clear cell cancer who had irAE in the initial ICI therapy. In this study, we reported the case of a patient with advanced renal clear cell cancer who developed serious irAEs but also achieved a partial remission of tumor after ICI combined with pazopanib in the first-line treatment. After intravenous methylprednisolone therapy for two weeks, the patient fully recovered from treatment-related toxicities. After a multidisciplinary treatment (MDT) discussion and a communication with the patient, the decision was made to undergo a new fully humanized programmed death 1 (PD-1) agent, zimberelimab, combined with pazopanib for immune restart therapy. After two cycles of treatment, the patient demonstrated a partial response (PR), and the disease remained in continuous remission without any irAE at our last follow-up after 14 months’ treatment. Re-challenging with immunotherapy after irAEs is an emerging strategy that offers the potential for additional clinical benefits to previously responding patients. However, careful patient selection and monitoring are essential to maximize the safety and efficacy of this approach. Frontiers Media S.A. 2023-10-17 /pmc/articles/PMC10616240/ /pubmed/37915573 http://dx.doi.org/10.3389/fimmu.2023.1270828 Text en Copyright © 2023 He, Wang, Sun, Du and Yu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology He, Shengxiu Wang, Liang Sun, Yan Du, Huakun Yu, Xiaomin Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer |
title | Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer |
title_full | Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer |
title_fullStr | Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer |
title_full_unstemmed | Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer |
title_short | Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer |
title_sort | case report: successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616240/ https://www.ncbi.nlm.nih.gov/pubmed/37915573 http://dx.doi.org/10.3389/fimmu.2023.1270828 |
work_keys_str_mv | AT heshengxiu casereportsuccessfulimmunecheckpointinhibitorbasedrechallengeinapatientwithadvancedrenalclearcellcancer AT wangliang casereportsuccessfulimmunecheckpointinhibitorbasedrechallengeinapatientwithadvancedrenalclearcellcancer AT sunyan casereportsuccessfulimmunecheckpointinhibitorbasedrechallengeinapatientwithadvancedrenalclearcellcancer AT duhuakun casereportsuccessfulimmunecheckpointinhibitorbasedrechallengeinapatientwithadvancedrenalclearcellcancer AT yuxiaomin casereportsuccessfulimmunecheckpointinhibitorbasedrechallengeinapatientwithadvancedrenalclearcellcancer |